FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 29, Issue 4, Pages 399-409
Publisher
Informa UK Limited
Online
2020-03-17
DOI
10.1080/13543784.2020.1740680
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
- (2020) Marta Canel et al. eLife
- Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
- (2019) Yu Pan et al. OncoImmunology
- Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
- (2019) Maja J. A. de Jonge et al. Targeted Oncology
- Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
- (2019) Toshihiko Doi et al. Targeted Oncology
- A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK
- (2019) Xiaodong Feng et al. CANCER CELL
- A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
- (2019) Gabriel Mak et al. BRITISH JOURNAL OF CANCER
- Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study
- (2019) Dean A. Fennell et al. JOURNAL OF CLINICAL ONCOLOGY
- The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review
- (2019) Jin Zhou et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
- (2019) Carlos J Diaz Osterman et al. eLife
- Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer
- (2019) Haisheng Zhang et al. Cancer Discovery
- Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer
- (2019) Frank Aboubakar Nana et al. Cancers
- Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
- (2019) David E. Gerber et al. LUNG CANCER
- A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098
- (2018) Nicholas F Brown et al. NEURO-ONCOLOGY
- Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice
- (2018) Shaogang Sun et al. Scientific Reports
- Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
- (2018) Ulrich A. Hirt et al. Oncogenesis
- The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
- (2018) Stefanie Tiede et al. Oncogenesis
- The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
- (2018) Viktoria Laszlo et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
- (2018) Mei Zeng et al. eLife
- Role of Pyk2 in Human Cancers
- (2018) Ting Shen et al. MEDICAL SCIENCE MONITOR
- VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
- (2018) Ning Ji et al. Frontiers in Pharmacology
- IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks
- (2017) Bryan Serrels et al. Science Signaling
- Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma
- (2017) Arindam P. Ghosh et al. Oncotarget
- Inhibition of FAK kinase activity preferentially targets cancer stem cells
- (2017) Vihren N. Kolev et al. Oncotarget
- IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks
- (2017) Bryan Serrels et al. Science Signaling
- Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
- (2017) Aibin Zhang et al. Cancer Medicine
- Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy
- (2017) B Xu et al. Oncogenesis
- FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
- (2017) Stefan N. Symeonides et al. Journal for ImmunoTherapy of Cancer
- pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma
- (2017) Kamolrat Thanapprapasr et al. PLoS One
- A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2016) J. C. Soria et al. ANNALS OF ONCOLOGY
- A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
- (2016) Toshio Shimizu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling
- (2016) Xuguang Yang et al. CANCER RESEARCH
- Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
- (2016) Timothy A. Marlowe et al. MOLECULAR CANCER THERAPEUTICS
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Phosphorylation of phosphatidylinositol 4-phosphate 5-kinase γ by Akt regulates its interaction with talin and focal adhesion dynamics
- (2015) Oanh Thi Tu Le et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2015) Suzanne F. Jones et al. INVESTIGATIONAL NEW DRUGS
- Focal adhesion kinase overexpression and its impact on human osteosarcoma
- (2015) Ke Ren et al. Oncotarget
- A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells
- (2014) Jianliang Zhang et al. CELL CYCLE
- Targeting FAK in human cancer: from finding to first clinical trials
- (2014) Vita Golubovskaya Frontiers in Bioscience-Landmark
- Understanding the Roles of FAK in Cancer
- (2014) Hyunho Yoon et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
- (2014) I. M. Shapiro et al. Science Translational Medicine
- Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities
- (2013) Vita M. Golubovskaya et al. Anti-Cancer Agents in Medicinal Chemistry
- The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation
- (2013) Andrew J. Wiemer et al. BIOCHEMICAL PHARMACOLOGY
- pH sensing by FAK-His58 regulates focal adhesion remodeling
- (2013) Chang-Hoon Choi et al. JOURNAL OF CELL BIOLOGY
- Role of Focal Adhesion Kinase in Regulating YB–1–Mediated Paclitaxel Resistance in Ovarian Cancer
- (2013) Yu Kang et al. JNCI-Journal of the National Cancer Institute
- Nuclear FAK: a new mode of gene regulation from cellular adhesions
- (2013) Ssang-Taek Steve Lim MOLECULES AND CELLS
- RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
- (2013) Georgia Konstantinidou et al. Cancer Discovery
- A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo
- (2012) V. M. Golubovskaya et al. CARCINOGENESIS
- 387 The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer
- (2012) K.R. Auger et al. EUROPEAN JOURNAL OF CANCER
- Merlin, a multi-suppressor from cell membrane to the nucleus
- (2012) Lu Zhou et al. FEBS LETTERS
- Function of Focal Adhesion Kinase Scaffolding to Mediate Endophilin A2 Phosphorylation Promotes Epithelial-Mesenchymal Transition and Mammary Cancer Stem Cell Activitiesin Vivo
- (2012) Huaping Fan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
- (2012) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Cross talk between focal adhesion kinase and cadherins: Role in regulating endothelial barrier function
- (2011) Sadiqa K. Quadri MICROVASCULAR RESEARCH
- Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
- (2011) J. B. Stokes et al. MOLECULAR CANCER THERAPEUTICS
- Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model
- (2010) Cedo M Bagi et al. CANCER BIOLOGY & THERAPY
- PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments
- (2010) Isabelle Tanjoni et al. CANCER BIOLOGY & THERAPY
- Knock-in Mutation Reveals an Essential Role for Focal Adhesion Kinase Activity in Blood Vessel Morphogenesis and Cell Motility-Polarity but Not Cell Proliferation
- (2010) Ssang-Taek Lim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- FAK overexpression and p53 mutations are highly correlated in human breast cancer
- (2009) Vita M. Golubovskaya et al. INTERNATIONAL JOURNAL OF CANCER
- Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271
- (2008) W. G. Roberts et al. CANCER RESEARCH
- Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation
- (2008) C. K. Sun et al. CARCINOGENESIS
- Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK
- (2008) Sara M. Weis et al. JOURNAL OF CELL BIOLOGY
- Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation
- (2008) Ssang-Taek Lim et al. MOLECULAR CELL
- p53 regulates FAK expression in human tumor cells
- (2007) Vita M. Golubovskaya et al. MOLECULAR CARCINOGENESIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now